ACCEL Lite: Featured ACCEL Interview With Robert Schwartz and Michael Reardon
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Release Date: 06/04/2019
EMPACT-MI Results: Empagliflozin After Acute Myocardial Infarction
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk. In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial.
info_outline
From JACC: HFpEF: Practical Guidance for Clinicians
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
About half of patients with chronic heart failure have an ejection fraction >40%. Therapy for patients in this group has been challenging until recently; few therapies have been effective in improving clinical outcomes in this population. Recently, data from several clinical trials of SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), Angiotensin-receptor neprilysin inhibitors (ARNI), and GLP-1 receptor agonists, however, have offered potential for targeted therapy in this population. Meanwhile, device therapy continues to evolve for this group. In this...
info_outline
From JACC: Aortic Valve Calcium and the Long-Term Risk of Incident Severe AS
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Aortic valve disease is often identified too late before clinicans can provide meaningful prevention. Identifying aortic valve calcium opens the door for potential prevention of progression: a phenotype researchers could build randomized controlled trials around. In this interview, Richard A. Chazal MD, MACC and Michael J. Blaha, MD, MPH discuss Prevalence of Aortic Valve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis. Podcasts |
info_outline
From JACC: Low-Density Lipoprotein Cholesterol Testing Following MI Hospitalization Among Medicare Beneficiaries
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
After a heart attack, it is important to lower cholesterol levels to prevent future heart attacks. Monitoring cholesterol levels on treatment is just as important as monitoring blood pressure levels on treatment to make sure that the medicines are having the desired effect. In this interview, C. Noel Bairey Merz, MD, FACC, and Vera Bittner, MD, MSPH, FACC, discuss Low-Density Lipoprotein Cholesterol Testing Following MI Hospitalization Among Medicare Beneficiaries. Podcasts |
info_outline
JACC State-of-the-Art Review: Racial and Ethnic Disparities in Perioperative Health Care Among Patients Undergoing Cardiac Surgery
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
This episode covers a review on disparities in cardiovascular perioperative health care. The writers propose actionable solutions utilizing multidisciplinary perspectives from cardiology, cardiac surgery, cardiothoracic anesthesiology, critical care, medical ethics, and health disparity experts. In this interview, Adam J. Milam, MD, PhD, and Clyde W.Yancy, MD, MSc, MACC, discuss the JACC State-of-the-Art Review: Racial and Ethnic Disparities in Perioperative Health Care Among Patients Undergoing Cardiac Surgery. Podcasts | |
info_outline
From JACC: National Trends in Coronary Artery Disease Imaging: Associations With Health Care Outcomes and Costs
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Cardiac imaging is increasingly used in the workup of coronary artery disease, with growth greatest for CCTA and with falling use of SPECT. Because of the low cost of computed tomography, this growing use of imaging has had only a small impact on cost of provision of diagnostic imaging in this population. In this interview, Jonathan R. Weir-McCall, PhD, and Christopher M. Kramer, MD, FACC, discuss From JACC: National Trends in Coronary Artery Disease Imaging: Associations With Health Care Outcomes and Costs. Podcasts | |
info_outline
ACCEL Lite: Top Takeaways from the AFib Guidelines
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In this interview, José A. Joglar, MD, FACC, and Joseph E. Marine MD, MBA, FACC, discuss the top takeaways from the latest atrial fibrillation (AFib) guideline, which provides new and updated recommendations for preventing and optimally managing AFib. Podcasts | |
info_outline
ACCEL Lite: From JACC: Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
A study provides new data for patients with genetic heart disease (GHD) and exercise recommendations. For decades, those with GHD were excluded from exercise and sports participation. This has led to poor exercise tolerance, increased risk for CAD and poor outcomes in this group related to reduced fitness. This study helps frame that those with GHD are unique and as a result, require an individualized approach to care. After expert consultation, patients with GHD can often be safe to participate in exercise including competitive sports. This is a first step in the direction of...
info_outline
AHA Late-Breaker ARTESiA: Apixaban for the Prevention of Stroke in Patients With Subclinical AF
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke. The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patient risk of stroke compared to treatment with aspirin, but is associated with an increased risk of bleeding. In this interview, Jeff S. Healey, MD, and Thomas F. Deering MD, FACC, discuss AHA Late-Breaker: Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation. ...
info_outline
ACCEL Lite: Behind the ACC 2023 Guideline for Chronic CAD: Conversations and Controversies
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
The 2023 guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. In this interview, Kristin Newby, MD, FACC, and Nanette Kass Wenger MD, MACC, discuss Behind the ACC 2023 Guideline for Chronic CAD: Conversations and Controversies. Podcasts | |
info_outlineIn this interview, Robert Schwartz and Michael Reardon discuss the Evolut Low Risk trial (Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality).